Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (September 2006)
22 slides from Lisata Therapeutics's investor presentation, Sep 6, 2006
Slide 1: NeoStem: Your Cells, Your Use
neostem Your Cells your use www.neostem.com NeoStem A subsidiary of Phase III Medical, Inc.
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENT S THIS PRESENTATION CONTAINS "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH FORWARD-LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORM
Slide 3: Researchers racing to develop stem cell treatments
Medical researchers, scientists, institutions, physicians, pharmaceutical companies, and biotechnology companies are racing to develop treatments of many diseases using stem cells
Slide 4: NeoStem specializes in adult stem cell collection and storage
NeoStem is the first company that specializes in thecollection, processing, and long-term storage of adult stemcells for autologous use (Your cells for Your use) Two patent applications filed on collection and storage process Multiple use Unique biobank being developed
Slide 5: Diseases Treatable with Stem Cells
Disease Treatable with Stem Cells TODAY o Leukemias o Lymphoma o Multiple Myeloma o Radiation Sickness o Autoimmune Dx o Tissue Repair & Burns o Breast & Ovarian Cancer FUTURE POSSIBILITIES o Diabetes o Cardiovascular Dx o Spinal Cord Injuries o Skin Rejuvenation o Rheumatologic o Orthopaedic oStrok
Slide 6: Stem Cell Origination
Stem Cell Origination o Controversial o Embryo o Fetal Tissue o Non-Controversial o Umbilical Cord Blood o Bone Marrow o Adult Peripheral Blood (NeoStem)
Slide 7: Who should bank their stem cells?
Who should bank their stem cells? o Health conscious individuals o Individuals with family histories of heart disease, diabetes or cancer o Individuals diagnosed with cancer o Individuals that are exposed to radiation or harmful toxins because of their jobs o "First Responders," who may be exposed t
Slide 8: Stem Cells and Pluripotency
Stem Cells and Pluripotency Stem Cell -PRIMITIVE AND THUS UNSPECIALIZED IVEAN S UN ALI -SELF-RENEWING -CAN DIFFERENTIATE INTO CELLS -CAN FF AT N ES WITH SPECIFIC FUNCTIONS SPE I IONS EctodermEctoderm Skin Hair Brain Nerves Etc. SkinHairBrainNervesEtc. Mesoderm Mesoderm Endoderm Endoderm Cardiac Skel
Slide 9: Autologous vs. Allogeneic Stem Cells
Autologous vs. Allogeneic Stem Cells Autologous Allogeneic Tissue Matching Not Required Required Rejection No Yes Graft v. Host No Yes Engraftment Faster Slower Immune Recon. Faster Slower HIV, Hepatitis etc. from Donor None Possible
Slide 10: Appeal to Insurance Companies - Savings
Appeal to Insurance Companies -$avings Autologous Allogeneic Hospitalization Short (<5 days) Long (>30 days) Time to Tx 1-2 days 90 days (avg.) Cost of Cells ~$6,000 >$22,000 Total Cost of Tx ~$50,000 $300 -$500 K Minority Avail. With Storage Very Low Match Avail. Not Applicable <50% Post -Tx Drugs
Slide 11: Intellectual Property
Intellectual Property o NeoStem has two pending U.S. patent applications describing key aspects of our process. Theseapplications are: - Elective Collection and Banking of Autologous Peripheral Blood Stem Cells. Publication Number 20040258673, Application Number 10/819,342, Priority Date April 2003
Slide 12: Intellectual Property (Cont.)
Intellectual Property (Cont.) - System Capable of Treating and Defining Various Disease States Using Stem Cells. Publication Number 20040265281, Application Number 10/819,398 Priority Date April 2003 o This pending application addresses the use of stored stem cells to form the basis for a data set t
Slide 13: Radiation Sickness (Hematopoietic Syndrome)
Radiation Sickness (Hematopoietic Syndrome) At 3.5 Gy 50% will die within 60 days w/o intervention Primary cause of death is infection Individuals exposed to 0.7 - 4.0 grays (Gy) will develop syndrome Rescue through Stem Cell transplant - treatment of choice Success rate very high when administered
Slide 14: Percutaneous Autologous Bone Marrow Grafting for Nonunions
Hernigou P et al. J Bone & Joint Surg 87A: 1430, 2005 FractureFractureN o n u n i o n No n u n i o n 1 m p o s t B M S C 1 mpo s t BMSC2 m p o s t B M S C 2 mpo s t BMSC3 m p o s t B M S C 3 mpo s t BMSCPercutaneous Autologous Bone Marrow Grafting for Nonunions
Slide 15: Chronic Heart Disease
Chronic Heart Disease o 5 million people in U.S. have chronic heart disease - 550K new diagnoses each year o Until now no effective therapy o Adult stem cells are being used to repair heart muscle o American Heart Association ranks restoration of failing hearts by adult stem cells among top 10 lifes
Slide 16: Potential Routes of Direct Delivery of Stem Cells to Heart
A. Direct intramyocardial through the epicardium B. Direct intramyocardial via the endocardium C. Intracoronary D. Retroperfusion via the cardiac veins A.Direct intramyocardial through the epicardiumB.Direct intramyocardial via the endocardiumC.IntracoronaryD.Retroperfusion via the cardiac veins A B
Slide 17: University of Pittsburgh School of Medicine
University of Pittsburgh School of Medicine • 20 patients w/ severe chronic heart disease - NY Heart Assoc Classification III & IV - 35% ejection fraction (55% normal adult) • 10 patients received by-pass surgery & adult stem cells during surgery • 10 patients received by-pass surgery only • At six
Slide 18: Texas Heart Institute
Texas Heart Institute o Post-AMI Trial o 14 patients with an average age of 56 received the stem cell therapy o 7 patients served as a control group o At 4 months, the treated patients had a sustained improvement in pumping power and ability to supplyblood to the body o FDA Approved Trial in US Marc
Slide 19: From: Evangelos V. Badiavas and Vincent Falanga Arch.Dermatol. 139:510, 2003
From: Evangelos V. Badiavas and Vincent Falanga Arch.Dermatol. 139:510, 2003
Slide 20: Comp Table
Comp Table Capital Raised in 2005 Net 52 last 12 2005 Income/ Current Week 52 Week Market Shares Months Revenues (Loss) Company Smbl Price Hi Low Cap (Mil) O/S (Mil) (Mil) (000) (000) Celgene Corp CELG $42.5 $49.4 $22.6 $14,903.0 350.7 $30.0 $536,941.0 $63,660.0 Geron Corp GERN $7.0 $12.2 $6.0 $463.
Slide 21: Management/Directors/Staff
Management/Directors/Staff o Robin Smith, M.D., MBA, NeoStem Chairman of the Board and CEO, Chairman Advisory Board of China Biopharmaceuticals (OTC BB: CHBP), Chairman of NYU-Hospital for Joint Diseases o Mark Weinreb, NeoStem Director and President, Former Owner, Bio Health Laboratories o Larry A.
Slide 22: Contact Information
Contact Information NeoStem, Inc. 420 Lexington Avenue Suite 450 New York, NY 10170 Main Phone: (212) 584-4180 Fax: (646) 514-7787 Web Site: www.neostem.com